PRV UL4 is a promotor of NLRP3 inflammasome activation. by Xiaohua Zhang (350570)

Subjects:

The UL4 null mutation alleviated inflammasome activation in PRV-infected cells. by Xiaohua Zhang (350570)

Subjects:

PRV UL4 is a promotor of NLRP3 inflammasome Activation. by Xiaohua Zhang (350570)

Subjects:

Sequence of UL4 is involved in inflammasome activation. by Xiaohua Zhang (350570)

Subjects:

PRV UL4 protein facilitates ASC oligomerization and speck formation by promoting ASC phosphorylation. by Xiaohua Zhang (350570)

Subjects:

Data for Figs S1A–S1C, S2A, S2C–S2L, S3C–S3F, S4A–S4J. by Xiaohua Zhang (350570)

Subjects:

Data for Figs 1A–1I, 2A–2J, 3B–3H, 4A–4L, 5A–5C, 6A–6C, 6E, by Xiaohua Zhang (350570)

Subjects:

Data for Figs 8A–8H, 9A–9K, 10A–10I. by Xiaohua Zhang (350570)

Subjects:

Viral UL4 protein promotes pyroptosis in macrophage cells. by Xiaohua Zhang (350570)

Subjects:

The UL4 mutation alleviates inflammation in PRV-infected pigs. by Xiaohua Zhang (350570)

Subjects:

PRV UL4 augments ASC oligomerization and speck formation. by Xiaohua Zhang (350570)

Subjects:

PRV UL4 interacts with ASC. by Xiaohua Zhang (350570)

Subjects:

The UL4 null mutation alleviates inflammasome activation in PRV-infected cells. by Xiaohua Zhang (350570)

Subjects:

Loxoprofen and SB225002 administration decreased sound stress exposure-induced hyperalgesia. by Satoka Kasai (3861115)

“…Mice treated with loxoprofen (500 mg/kg) or SB225002 (3 mg/kg) showed significantly decreased response times to the filament compared to Stress + saline group (Stress + loxoprofen (500 mg/kg), 30 min after administration, **<i>P</i> < 0.01, 60 min after administration, ***<i>P</i><i> <i><</i> </i>0.001; Stress + SB225002 (3 mg/kg), 60 min after administration, *<i>P</i> < 0.05). 2-way ANOVA <i>post-hoc</i> Bonferroni test. …”

Irradiation effect on <i>D. melanogaster</i> male sterility. GLM model values are shown. Values in boldface indicate significant differences (p < 0.05). by Flavia Cerasti (21655934)

Subjects:

Changes in the eGFRs and serum potassium levels compared with values at the end of 1 month of treatment in all patients over time. by Jia Song (495396)

Subjects:

Effect of ex vivo treatment with rhTGFβ1 or a TGFβ1 inhibitor on monocyte responses to rgE stimulation. Monocytes and NK cells purified from PBMC collected from 10 RZV recipients (demographics in S4 Table) before vaccination (D0) and 90 days post-vaccination (D90) were combined ex vivo and stimulated with VZV-rgE. A subset of D0 monocyte & NK cocultures was also treated with the TGFβ1 inhibitor LY (D0 LY), and a subset of D90 cocultures were supplemented with rhTGFβ1. The graph shows individual data points, means and p values calculated by Friedman test for repeated measures with FDR correction. LY treatment of cells collected on D0 significantly increased their activation to levels similar to D90. Conversely, treatment of D90 cells with rhTGFβ1 significantly decreased their activation to levels similar to D0. by Michael J. Johnson (5818168)

“…Conversely, treatment of D90 cells with rhTGFβ1 significantly decreased their activation to levels similar to D0.…”

The levels of independent test variables in the experimental study. by Peng Zhao (128233)

Subjects:

Differential miRNA target gene pathway enrichment bubble map. by Zhaowen Tan (12283502)

Subjects:

qRT-PCR results of differentially expressed miRNAs in rats’ myocardial tissue after training. by Zhaowen Tan (12283502)

Subjects: